Chemoimmunotherapy with levamisole in acute lymphoblastic leukemia

Area of Science:

• Immunology
• Pediatric Oncology
• Clinical Pharmacology

Background:

• Acute lymphoblastic leukemia (ALL) is a common childhood cancer requiring effective maintenance therapies to prevent relapse.
• Optimizing post-remission strategies is crucial for improving long-term outcomes in ALL survivors.
• The role of immunomodulatory agents in ALL maintenance therapy warrants further investigation.

Purpose of the Study:

• To evaluate the efficacy of levamisole as a maintenance therapy in patients with acute lymphoblastic leukemia (ALL).
• To assess the impact of levamisole on relapse rates and duration of complete remission (CR) in low-risk and high-risk ALL patients.
• To investigate the effect of levamisole on cellular immunity using the DNCB skin test.

Main Methods:

• Randomized controlled trial comparing levamisole versus no levamisole in ALL patients in CR on maintenance therapy.
• Stratification of patients into low-risk and high-risk groups based on protocol-specific criteria.
• Monitoring of relapse rates, duration of CR, and overall survival.
• Assessment of immune status via DNCB skin test positivity at specified intervals.

Main Results:

• Levamisole significantly reduced relapse rates in low-risk ALL patients in both protocols (P < 0.025 and P < 0.05).
• Higher CR rates at 48 months (67% vs. 49%) and 36 months (78% vs. 61%) were observed in low-risk patients receiving levamisole.
• Levamisole treatment was associated with improved DNCB skin test positivity, indicating enhanced cellular immunity (P < 0.025).

Conclusions:

• Levamisole maintenance therapy prolongs CR duration and improves survival in low-risk ALL patients.
• Levamisole demonstrates immunomodulatory effects beneficial in the post-remission setting of ALL.
• Further research into levamisole's role in high-risk ALL populations may be warranted.